ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 249 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $61,037,526 | +422.5% | 2,928,864 | +500.5% | 0.03% | +400.0% |
| Q2 2023 | $11,682,139 | +35329.4% | 487,772 | -72.2% | 0.01% | -68.4% |
| Q1 2023 | $32,973 | +72.3% | 1,752,013 | +45.7% | 0.02% | +72.7% |
| Q4 2022 | $19,141 | -99.7% | 1,202,329 | +226.1% | 0.01% | +175.0% |
| Q3 2022 | $6,032,000 | -49.9% | 368,678 | -56.8% | 0.00% | -42.9% |
| Q2 2022 | $12,037,000 | -54.3% | 854,277 | -21.4% | 0.01% | -50.0% |
| Q1 2022 | $26,324,000 | +66.3% | 1,086,889 | +60.3% | 0.01% | +75.0% |
| Q4 2021 | $15,825,000 | +8891.5% | 678,013 | +6290.3% | 0.01% | – |
| Q3 2021 | $176,000 | -97.1% | 10,610 | -95.7% | 0.00% | -100.0% |
| Q2 2021 | $6,023,000 | +94.9% | 246,931 | +106.1% | 0.00% | +100.0% |
| Q1 2021 | $3,090,000 | -87.6% | 119,800 | -74.4% | 0.00% | -88.9% |
| Q4 2020 | $24,972,000 | +2.3% | 467,111 | -21.0% | 0.02% | -40.0% |
| Q3 2020 | $24,401,000 | -39.3% | 591,532 | -28.7% | 0.03% | -45.5% |
| Q2 2020 | $40,203,000 | +209.1% | 829,432 | +169.4% | 0.06% | +89.7% |
| Q1 2020 | $13,006,000 | -69.2% | 307,846 | -68.9% | 0.03% | -45.3% |
| Q4 2019 | $42,280,000 | +15.1% | 988,313 | -3.2% | 0.05% | -8.6% |
| Q3 2019 | $36,740,000 | +68.6% | 1,020,864 | +25.2% | 0.06% | +75.8% |
| Q2 2019 | $21,794,000 | +165.1% | 815,335 | +166.3% | 0.03% | +175.0% |
| Q1 2019 | $8,220,000 | -43.9% | 306,161 | -66.2% | 0.01% | -47.8% |
| Q4 2018 | $14,641,000 | +68.4% | 905,416 | +116.2% | 0.02% | +109.1% |
| Q3 2018 | $8,693,000 | -27.1% | 418,743 | -46.4% | 0.01% | -31.2% |
| Q2 2018 | $11,920,000 | -19.8% | 780,624 | +18.0% | 0.02% | -20.0% |
| Q1 2018 | $14,861,000 | +468.7% | 661,358 | +662.1% | 0.02% | +400.0% |
| Q4 2017 | $2,613,000 | +12.5% | 86,781 | +40.7% | 0.00% | 0.0% |
| Q3 2017 | $2,323,000 | -85.9% | 61,669 | -89.5% | 0.00% | -86.2% |
| Q2 2017 | $16,425,000 | +1143.4% | 588,922 | +1432.4% | 0.03% | +1350.0% |
| Q1 2017 | $1,321,000 | -97.8% | 38,431 | -98.2% | 0.00% | -98.4% |
| Q4 2016 | $61,261,000 | +778.2% | 2,124,156 | +868.7% | 0.13% | +975.0% |
| Q3 2016 | $6,976,000 | +61.5% | 219,284 | +64.8% | 0.01% | +20.0% |
| Q2 2016 | $4,320,000 | -72.5% | 133,097 | -76.3% | 0.01% | -74.4% |
| Q1 2016 | $15,684,000 | -4.1% | 560,955 | +22.3% | 0.04% | +14.7% |
| Q4 2015 | $16,356,000 | -37.8% | 458,785 | -42.3% | 0.03% | -33.3% |
| Q3 2015 | $26,291,000 | -40.2% | 795,025 | -24.3% | 0.05% | -38.6% |
| Q2 2015 | $43,975,000 | +163.8% | 1,050,029 | +105.3% | 0.08% | +167.7% |
| Q1 2015 | $16,671,000 | +168.0% | 511,522 | +161.1% | 0.03% | +138.5% |
| Q4 2014 | $6,220,000 | +39.4% | 195,910 | +8.7% | 0.01% | +8.3% |
| Q3 2014 | $4,461,000 | +27.4% | 180,169 | +16.2% | 0.01% | +20.0% |
| Q2 2014 | $3,501,000 | -19.6% | 155,000 | -13.4% | 0.01% | -16.7% |
| Q1 2014 | $4,353,000 | -36.7% | 178,900 | -34.9% | 0.01% | -45.5% |
| Q4 2013 | $6,872,000 | -53.6% | 275,000 | -49.0% | 0.02% | -53.2% |
| Q3 2013 | $14,826,000 | +48.9% | 539,720 | -1.6% | 0.05% | +56.7% |
| Q2 2013 | $9,956,000 | – | 548,553 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |